Table 1.

Qualitative patient interview eligibility criteria

	Inclusion criteria	Exclusion criteria
Demographics	• Male or female ≥ 18 years at the time of signing informed consent • Speak fluent English • Able to hold a 60-min conversation over the telephone independently • Has access to a computer	• < 18 years at the time of signing informed consent • Unable to speak fluent English • Unable to independently hold a 60-min conversation over the telephone • Does not have access to a computer
Diagnosis	• Stage 2/3a/3b CKD. Duration > 3 months • Serum creatinine-based eGFR ≥ 30 and ≤ 89 mL/min/1.73 m2 (CKD-EPI)	• No CKD. Stage 1/4 CKD • Serum creatinine-based eGFR < 30 and > 89 mL/min/1.73 m2 (CKD-EPI)
Comorbidities	• Type 2 diabetes mellitus (≤ 50% of study population) • Type 1 diabetes mellitus (≤ 5% of study population) • Hyperuricaemia (≤ 30% of study population)	• Type 2 diabetes mellitus (> 50% of study population) • Type 1 diabetes mellitus (> 5% of study population) • Hyperuricaemia (> 30% of study population) • Autosomal dominant or autosomal recessive polycystic kidney disease • Lupus nephritis or ANCA-associated vasculitis • Autoimmune kidney diseases including glomerulonephritis • Congenital urinary tract malformations
Therapy		• Current (or within 90 days) chronic or intermittent haemodialysis or peritoneal dialysis • Receiving cytotoxic therapy, immunosuppressive therapy or other immunotherapy for primary or secondary renal disease within 6 months prior to enrolment • Previously received an organ transplant • NYHA class IV Congestive Heart Failure at the time of enrolment • Myocardial infarction, unstable angina, stroke or transient ischaemic attack within 12 weeks prior to enrolment

ANCA anti-neutrophil cytoplasmic antibody, CKD chronic kidney disease, eGFR estimated glomerular filtration rate, NYHA New York Heart Association